Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Immunovia AB ( (SE:IMMNOV) ) is now available.
Immunovia AB has proposed a reverse share split, consolidating 100 existing shares into one, to optimize the number of shares for the company. This initiative, subject to approval during an Extraordinary General Meeting in January 2026, aims to improve operational alignment and shareholder value by simplifying share ownership and adjusting the share’s quota value. Stakeholders won’t need to take action as the process will be executed automatically. The reverse split seeks to bolster Immunovia’s market positioning amidst its focus on early cancer detection.
More about Immunovia AB
Immunovia is a diagnostic company dedicated to improving survival rates for pancreatic cancer patients through early detection. The company develops and markets blood-based tests to identify proteins and antibodies indicative of pancreatic cancer, collaborating with healthcare providers and experts to serve high-risk individuals, primarily focusing on the U.S. market.
Average Trading Volume: 6,356,626
Technical Sentiment Signal: Sell
Current Market Cap: SEK165.8M
Find detailed analytics on IMMNOV stock on TipRanks’ Stock Analysis page.